Semaglutide: The most effective weight loss drug for type 2 diabetes

Semaglutide:Themosteffectiveweightlossdrugfortype2diabetes

WhatisSemaglutidePowder?

Semaglutidepowderisaglucagon-likepeptide-1receptoragonistusedinindividualswith type2diabetesasanadditiontodietandexercisetoimproveglycemiccontrol.Semaglutide powderisaGLP-1mimichaving94%sequencehomologytohumanGLP-1.Itcanbindto theGLP-1receptorandactivatethereceptortolowerbloodsugarbyboostinginsulin productionanddecreasingglucagonsecretionasaGLP-1receptoragonist.Furthermore, semaglutidepowdercanactonthedigestivetractbydelayinggastrointestinalemptyingto inducefullness;onthebrainbysuppressingappetite;andonthecirculatorysystemby repairingdamagedintimaandimprovingendothelialfunction.

HowDoesSemaglutideWork?

Semaglutidepowerisanagonistoftheglucagon-likepeptide-1receptor.Itbooststhe productionofinsulin,ahormonethatreducesbloodsugarlevels,byimitatingtheeffectof theincretinglucagon-likepeptide-1(GLP-1).Italsoappearstostimulatetheproliferationof pancreaticbetacells,whichareresponsibleforinsulingenerationandrelease.Inaddition, AASrawsemaglutidepowderhasaabilitytodecreaseglucagonproduction,ahormonethat stimulatesglycogenolysis(thereleaseofstoredcarbsfromtheliver)andgluconeogenesis (thecreationofnewglucose).Itreducesfoodintakebysuppressinghungerandslows digestioninthestomach,whichaidsinweightloss.Itsuppressesappetite,foodcravings, andfatstorage.

TheResearchonSemaglutide.

SemaglutideisamedicationthatwasoriginallydevelopedtotreatdiabetesHowever,ithas gainedpopularityasaweightlossdrugafteritwasfoundtoeffectivelyhelpindividualslose weight,includingtheworld'ssecondrichestman,ElonMusk.Recently,the study----Once-WeeklySemaglutideinAdolescentswithObesity----publishedintheNew EnglandJournalofMedicine(NEJM)hasfoundthatsemaglutidemayalsohelpobese adolescentsreduceweightandpromotehearthealth.

②KeyFindings

Obeseadolescentswhotookweeklysemaglutidesawa16.1%increaseinbodymassindex (BMI)inaninternationalphase3aclinicaltrial,comparedtoa0.6%increaseintheplacebo group.

Semaglutideisaglucagon-likepeptide1(GLP-1)receptoragonistthatcanreduceappetite, diet,andcalorieintake,makingiteffectiveforweightloss.

Alarge-scaleclinicaltrialshowedthatsemaglutidehasanamazingeffectasaweightloss medicine,withthetreatedgrouplosinganaverageof15.3kg.

InJune2021,theU.S.FoodandDrugAdministration(FDA)approvedthemarketingof semaglutide(Semaglutide),aweight-lossdrugwithatradenameofWegovy.

Arecentstudyhasfoundthatsemaglutideoutperformedplacebointermsofweightloss andimprovementofcardiometabolicriskfactorsinobeseadolescents

Aftertakingsemaglutide,cardiovascularriskfactorssuchaswaistcircumference,blood glucoseindexHbA1c,totalcholesterol,low-densityandverylow-densitylipoprotein cholesterol,triglycerides,andtriglyceridesimproved.

Thesemaglutidegroupoutperformedtheplacebogrouponweight-relatedqualityoflife measures,owingmostlytohigherphysicalcomfortscores.

③Conclusion

Semaglutidehasbeenshowntobeaneffectiveweightlossmedication,andrecentresearch hasdemonstratedthatitmayalsobebeneficialforobeseadolescents.Whilethe medicationisassociatedwithsomegastrointestinalsideeffects,ithasbeenfoundto improvecardiovascularriskfactorsandqualityoflifemeasures.

king@aasraw.com

SourceOrigin:https://wwwncbinlmnihgov/pmc/articles/PMC9997064/

BenefitsofUsingSemaglutidePowder

Semaglutidepowderisaversatilemedicationthatoffersarangeofbenefitsforindividuals withvariousmedicalconditions.Someofthemostcommonconditionsthatcanbenefit fromtheuseofAASrawSemaglutidepowderincludingType2DiabetesMellitus, caidiovascularrisks,obesityandAlzheimer.

①LoweringBloodGlucoseLevels

SemaglutidepowderisaGLP-1receptoragonistthatiseffectiveinloweringbloodglucose levelsinpeoplewithtype2diabetesbyseveralmechanisms.Itstimulatesinsulinsecretion, whichhelpstomoveglucosefromthebloodintothecellswhereitcanbeusedforenergy.

Semaglutidealsosuppressesglucagonsecretion,whichreducesglucoseproductionbythe liver.Additionally,itslowsdowngastricemptying,whichreducestherateatwhichglucose entersthebloodstreamafterameal.

Inclinicaltrials,semaglutidehasbeenshowntosignificantlyreduceHbA1clevels,whichis anindicatoroflong-termbloodglucosecontrolIntheSUSTAIN-1trial,semaglutidereduced HbA1clevelsby15%comparedtoplacebo,andintheSUSTAIN-10trial,itreducedHbA1c levelsby1.8%comparedtoplacebo.Semaglutidehasalsobeenshowntobeeffectivein reducingfastingplasmaglucoselevelsandpostprandialglucoseexcursions.

②ReducingRiskofCardiovascularEvents

Semaglutidepowderhasbeenshowntoreducetheriskofmajoradversecardiovascular events(MACE)suchascardiovasculardeath,nonfatalmyocardialinfarction,andnonfatal strokeinadultswithtype2diabetesandestablishedcardiovasculardisease.Thisbenefit wasobservedintheSUSTAIN-6andPIONEER-6trials,whichshowedasignificantreduction inMACEwithsemaglutidetreatmentcomparedtoplacebo.Moreover,Semaglutidepowder hasbeenshowntoimproveseveralcardiovascularriskfactorssuchasbloodpressure,lipid profile,andmarkersofinflammationinpeoplewithtype2diabetes.IntheSUSTAIN-6trial, semaglutidewasassociatedwithasignificantreductioninsystolicbloodpressureand improvementinlipidprofile,includingreductionsintotalcholesterol,LDLcholesterol,and triglycerides.

③LosingWeight

Semaglutidepowderisapotentweightlossagent,eveninpeoplewithoutdiabetes. Semaglutideworksbyreducingappetiteandcalorieintake,leadingtoadecreaseinbody weight.Thisisachievedthroughitseffectsonthecentralnervoussystemandthe gastrointestinaltract.Semaglutideactsonthehypothalamus,whichregulateshungerand satiety,andreducesthedesiretoeatbyincreasingfeelingsoffullness.Additionally, semaglutideslowsdowngastricemptying,whichprolongsthefeelingoffullnessaftera mealandreducestheurgetoeat.

Clinicaltrialshavedemonstratedtheweightlossbenefitsofsemaglutide.IntheSTEP program,whichevaluatedtheuseofsemaglutideforweightmanagementinpeople

withoutdiabetes,semaglutidewasassociatedwithsignificantweightlosscomparedto placebo.Participantswhoreceivedonce-weeklysemaglutidelostanaverageof15%oftheir bodyweightover68weeks,whilethosewhoreceivedplacebolostonly2.4%.

Inpeoplewithtype2diabetes,semaglutidepowdercanleadtoadditionalweightloss benefits.IntheSUSTAIN7trial,whichevaluatedtheefficacyandsafetyofsemaglutidein peoplewithtype2diabetes,semaglutidewasassociatedwithasignificantreductionin bodyweightcomparedtoplacebo.Participantswhoreceivedsemaglutidelostanaverageof 4.6kg,whilethosewhoreceivedplacebolostonly1.2kg.

④TreatingAlzheimer’sDiseaseSymptom

Multiplepreclinicalstudieshaveshownthatsemaglutidepowderhasneuroprotective propertiesagainstamyloid-βplaquesinahumanneuroblastoma(SH-SY5Y)cellline, suggestingthatsemaglutidecanalleviateAlzheimer'sdiseasesymptom.Animalmodels havealsoshownthatsemaglutidehasneuroprotectiveeffectsonanimalmodels.According toNovoNordisk’sannouncement,theindicationofsemaglutidetabletsforAlzheimer’s disease(AD)isintheclinicalstage.TwoglobalPhaseIIItrials,EVOKEandEVOKEplus,are underway,andabout3,700volunteersareexpectedtoberecruited.Inthisstudy, comparedwithplacebo,evaluatethesuperiorityofsemaglutidetabletsoncognitive functioninsubjectswithmildcognitiveimpairment(MCI)ormilddementiacausedbyAD.

Precautions:Itiskeytopurchasingsemaglutidepowderfromreputablesources,otherwise,

king@aasraw.com

www.aasraw.com

youcannotgetthebestefficacyofsemaglutidepowder.Asaprofessionalsemaglutide powdermanufacturerandsupplier,AASrawaimtosupplypuresemaglutidepowder worldwide.Ifyouhaveneeds,AASraw’ssemaglutidepowderisagreatchoiceforyou.

TheSideEffectsofSemaglutidePowder?

Semaglutidepowder,likeanymedication,maycausesideeffects

①Commonsideeffectsareinclude:

Nausea

Vomiting

Diarrhea

Abdominalpain

Lossofappetite

Constipation

Headache

Fatigue

Dizziness

②Lesscommonbutmoreserioussideeffectsmayinclude:

Pancreatitis

Hypoglycemia(lowbloodsugar)

king@aasraw.com

Acutekidneyinjury

Diabeticretinopathycomplications

Gallbladderdisease

Allergicreactions

Thyroidtumors

Notes:Thedurationofsideeffectsofsemaglutidepowdercanvarydependingonthe individualandtheseverityofthesideeffects.Inmostcases,thesideeffectsofsemaglutide aretemporaryandwillimproveasyourbodyadjuststothemedication.Commonside effectssuchasnausea,diarrhea,vomiting,constipation,andheadachetypicallyresolve withinafewdaystoaweekIfyouexperienceanyunusualorseveresideeffectswhile takingsemaglutide,gotothedoctorpromptlyAdditionally,buyingsemaglutidepowder withhighqualityfromreliablesupplier,likeAASraw,iscrucial.

DosageandAdministrationofSemaglutidePowderforReference

Thedosageandadministrationofsemaglutidecanvarydependingontheindicationforuse.

Herearesomegeneralguidelines:

①Indication:Type2DiabetesMellitus

SubcutaneousInjection

king@aasraw.com

Week1-4:0.25mg/week

Week5andonward:0.5mg/week

Ifneeded,afteratleast4weeksonthe0.5-mgdose,increaseto1mgsubcutaneouslyonce weekly.

Ifneeded,afteratleast4weeksonthe1-mgdose,increaseto2mgsubcutaneouslyonce weekly;donotexceed2mg/week.

OralTablet

Day1-30:3mg/day

Day31andonward:7mg/day

Ifneeded,afteratleast30daysonthe7-mgdose,increaseto14mgorallyoncedaily.

Note:Donottaketwo7-mgtabletstoachievea14-mgdose

②Indication:ChronicWeightManagement

SubcutaneousInjection

Week1-4:0.25mg/week

Week5-8:0.5mg/week

Week9-12:1mg/week

Week13-16:1.7mg/week

Week17andonward:2.4mg/week(maintenancedose)

Initiatewithlowdoseandgraduallyescalatetomaintenancedosetominimize gastrointestinaladversereactions. Ifunabletotolerateadoseduringescalation,considerdelayingdoseescalationfor4weeks.

Ifunabletotoleratethemaintenancedoseof2.4mgonceweekly,maytemporarily decreaseto17mgonceweeklyforamaximumof4weeks;after4weeks,increasebackto maintenance24mgonceweekly;discontinueifnottoleratedafterthesecondattempt

Note:Thedosageandadministrationofsemaglutidepowdermayvarydependingonthe indicationforuse.Followtheinstructionsprovidedbyyourdoctororasindicatedonthe medicationlabel.Moreover,tryyourbesttobuypuresemaglutidepowdertoachievethe bestefficacy.

WheretobuySemaglutidePowder?

Semaglutidepowder,ahighlysought-aftermedicationforthetreatmentoftype2diabetes, hasbecomeincreasinglypopularamongpatientsseekingeffectivesolutionstomanage theircondition.Asaresult,onlinemarketplaceshaveemergedasaconvenientplatformfor

peopletobuysemaglutidepowderonline.Thesedigitalplatformsprovidecustomerswith theopportunitytocompareprices,readreviews,andaccessawiderangeofoptionstosuit theirneeds.However,itisessentialforcustomerstoexercisecautionwhenpurchasing semaglutidepowderonline,ascounterfeitorlow-qualityproductscouldpotentially compromisetheirhealth.Byconductingthoroughresearchandselectingareputableand certifiedseller,individualscanconfidentlypurchasesemaglutidepowderonlineand effectivelymanagetheirdiabeteswithease.

AASrawaimingtomanufacturingabdsupplyingchemicalintermediatesandactive pharmaceuticalingredients(APIs),isatrustedproviderofhigh-qualitysemaglutidepowder andotherrelatedproductsTheircommitmenttorigorousqualitycontrolandadherenceto industrystandardsensuresthatcustomersreceiveonlythebestproductsfortheirhealth andwell-being.ByshoppingatAASraw,individualsseekingsemaglutidepowdercanenjoya convenient,secure,andreliablepurchasingexperience,allwhilebenefitingfromtheir extensiveknowledgeandexpertiseinthefield.

Reference:

WeightLossOutcomesAssociatedWithSemaglutideTreatmentforPatientsWith OverweightorObesity.JAMANetwOpen.2022Sep1;5(9):e2231982.

king@aasraw.com

[2]WildingJPH,BatterhamRL,DaviesM,VanGaalLF,KandlerK,KonakliK,LingvayI, McGowanBM,OralTK,RosenstockJ,WaddenTA,WhartonS,YokoteK,KushnerRF;STEP1 StudyGroup.Weightregainandcardiometaboliceffectsafterwithdrawalof semaglutide:TheSTEP1trialextension.DiabetesObesMetab.2022Aug;24(8):1553-1564.

[3]GarveyWT,BatterhamRL,BhattaM,BuscemiS,ChristensenLN,FriasJP,JódarE,Kandler K,RigasG,WaddenTA,WhartonS;STEP5StudyGroup.Two-yeareffectsofsemaglutidein adultswithoverweightorobesity:theSTEP5trial.NatMed.2022Oct;28(10):2083-2091.

[4]KnudsenLB,LauJTheDiscoveryandDevelopmentofLiraglutideandSemaglutideFront Endocrinol(Lausanne)2019Apr12;10:155

[5]MahapatraMK,KaruppasamyM,SahooBM.TherapeuticPotentialofSemaglutide,a NewerGLP-1ReceptorAgonist,inAbatingObesity,Non-AlcoholicSteatohepatitisand Neurodegenerativediseases:ANarrativeReview.PharmRes.2022Jun;39(6):1233-1248.

king@aasraw.com